GIS3 Antibody

Shipped with Ice Packs
In Stock

Description

Table 1: Comparative Features of IgG Subclasses

PropertyIgG1IgG3
Hinge length15 aa62 aa
Half-life~21 days~7 days
ADCC activityModerateHigh
Complement activationModerateHigh
Fab flexibilityLimitedExceptional

Infectious Disease Neutralization

  • Influenza and SARS-CoV-2: IgG3 antibodies exhibit broad neutralization against antigenically drifted variants due to their extended hinge, which accommodates epitope variation . For example, IgG3 versions of monoclonal antibodies (mAbs) targeting SARS-CoV-2 spike protein showed 4–8x higher neutralization potency against Omicron variants compared to IgG1 .

  • HIV: IgG3 antibodies like CAP256-VRC26.25 demonstrate enhanced phagocytosis and trogocytosis via FcγRIIa binding, correlating with improved viral clearance .

Oncology

  • Anti-GM3 ganglioside antibodies: IgG3 mAbs (e.g., MAb-1) trigger strong ADCC against ovarian cancer cells, with >60% tumor growth inhibition in preclinical models .

  • Melanoma targeting: IgG3 antibodies (e.g., MG-21) mediate potent ADCC and complement-dependent cytotoxicity (CDC), suppressing tumor growth in murine models .

COVID-19 and IgG3 Dominance

  • IgG3 constituted >50% of anti-nucleocapsid responses in severe COVID-19 patients, linked to cytokine storms and ARDS .

  • Anti-spike IgG3 antibodies in convalescent plasma exhibited 54,284 m/z mass signatures, suggesting unique post-translational modifications (e.g., hyperglycosylation) that may influence pathogenicity .

Engineering for Stability

  • Engineered IgG3 variants with shortened hinges (e.g., IgG3*17 allotype) show reduced immunogenicity while retaining neutralization capacity .

  • Hinge modifications improve pharmacokinetics, increasing half-life from 7 to 14 days in primate studies .

Challenges and Future Directions

  • Half-life limitations: IgG3’s shorter half-life (vs. IgG1) is attributed to weak FcRn binding . Solutions include hybrid IgG1/IgG3 designs .

  • Clinical trials: The first human IgG3 therapeutic (anti-cancer mAb) entered Phase I trials in 2021, focusing on safety and effector function efficacy .

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
GIS3 antibody; YLR094CProtein GIS3 antibody
Target Names
GIS3
Uniprot No.

Target Background

Database Links

KEGG: sce:YLR094C

STRING: 4932.YLR094C

Subcellular Location
Cytoplasm. Nucleus.

Q&A

What is the optimal storage condition for maintaining GIS3 antibody activity?

GIS3 antibody requires storage at either -20°C or -80°C to maintain its activity and specificity . For long-term storage, -80°C is recommended to prevent freeze-thaw cycles that can degrade antibody performance. When working with the antibody, aliquoting into single-use volumes before freezing helps maintain consistency across experiments by avoiding repeated freeze-thaw cycles. The antibody should be thawed on ice prior to use and centrifuged briefly to collect contents at the bottom of the tube.

What are the validated applications for GIS3 antibody?

The GIS3 antibody has been validated for ELISA and Western Blot (WB) applications . For Western Blot applications, optimization typically includes testing different antibody dilutions (1:500 to 1:5000) and blocking conditions. For ELISA applications, both direct and sandwich ELISA formats can be employed, with typical working dilutions ranging from 1:1000 to 1:10000 depending on sample concentration and detection method sensitivity.

What is the reactivity profile of GIS3 antibody?

The GIS3 antibody has been specifically developed for reactivity with yeast species, particularly Saccharomyces cerevisiae (strain ATCC 204508 / S288c) . Cross-reactivity testing with other yeast species or organisms should be experimentally validated before use in comparative studies. When studying evolutionary conservation of GIS3 across species, alignment analysis of the immunogen sequence with potential target organisms is recommended prior to experimental validation.

How should I validate GIS3 antibody specificity in my experimental system?

Antibody validation should include positive and negative controls. The recombinant immunogen protein provided with the antibody (200μg) can serve as a positive control . For negative controls, consider using pre-immune serum provided with the antibody kit , as well as samples from GIS3 knockout strains if available. Western blot analysis should demonstrate a band of the expected molecular weight, while competing peptide assays can be used to confirm specificity.

How can I optimize GIS3 antibody for chromatin immunoprecipitation (ChIP) experiments?

While GIS3 antibody has not been specifically validated for ChIP, polyclonal antibodies can often be adapted for this application. Begin with standard crosslinking procedures using 1% formaldehyde for 10 minutes at room temperature. Initial antibody titration experiments should test concentrations from 1-10μg per IP reaction. Include appropriate controls such as IgG from the same species and input chromatin. Optimization may require adjusting sonication conditions, antibody concentration, and washing stringency. Validation should include qPCR of regions known to interact with GIS3 and negative control regions.

What strategies can resolve non-specific binding issues with GIS3 antibody in complex yeast lysates?

Non-specific binding can be addressed through several methodological approaches. Increase blocking stringency by using 5% BSA or 5% non-fat dry milk in TBS-T, extending blocking time to 2 hours at room temperature. Consider adding 0.1-0.5% non-ionic detergent (Triton X-100) to reduce hydrophobic interactions. Pre-adsorption of the antibody with yeast lysate from GIS3 knockout strains can reduce cross-reactivity. Additionally, increasing wash steps (at least 4-5 washes of 10 minutes each) with higher stringency buffers can significantly improve specificity.

How can I quantitatively assess post-translational modifications of GIS3 using this antibody?

For studying post-translational modifications (PTMs), combine the GIS3 antibody with techniques such as Phos-tag™ SDS-PAGE for phosphorylation analysis or co-immunoprecipitation followed by mass spectrometry. When analyzing phosphorylation states, treat samples with lambda phosphatase as a control. For quantitative western blots, use fluorescently-labeled secondary antibodies and include standardized loading controls. Consider two-dimensional gel electrophoresis followed by western blotting to separate different PTM forms before detection.

What are the key considerations when designing time-course experiments with GIS3 antibody?

Time-course experiments require careful planning to ensure consistent antibody performance across multiple time points. Prepare a master mix of antibody dilution sufficient for all samples to minimize technical variability. Include both technical and biological replicates (minimum n=3) for statistical validity. For Western blot time-course experiments, consider using the same membrane for all time points if possible, or include internal standardization samples across multiple membranes. For cell cycle analysis, synchronize yeast cultures using standard methods before sampling at defined intervals.

How should I approach comparing GIS3 expression across multiple yeast strains?

When comparing GIS3 expression across strains, standardize growth conditions, harvesting procedures, and protein extraction methods. Quantitative Western blot analysis should include housekeeping protein controls (such as actin or GAPDH) for normalization. Consider using fluorescently-labeled secondary antibodies for more accurate quantification than chemiluminescence. Statistical analysis should account for biological variation using appropriate tests (ANOVA with post-hoc tests for multiple comparisons). Include wild-type, knockout, and overexpression strains as reference points when available.

What controls are necessary when using GIS3 antibody in co-immunoprecipitation studies?

Co-immunoprecipitation experiments require rigorous controls to validate protein-protein interactions. Include input samples (pre-IP lysate), IgG control IP from the same species as the GIS3 antibody, and no-antibody bead controls. For reverse co-IP validation, use antibodies against suspected interacting partners to precipitate complexes, then probe for GIS3. Consider crosslinking approaches for transient interactions. Validate interactions using orthogonal methods such as proximity ligation assay or yeast two-hybrid systems.

How should I interpret differences in GIS3 antibody signal between different experimental conditions?

Interpreting signal differences requires consideration of multiple factors. Quantify band intensity using software such as ImageJ, normalizing to loading controls. Perform statistical analysis using appropriate tests (t-test for two conditions, ANOVA for multiple conditions). Consider biological significance thresholds (typically 1.5-fold or 2-fold changes minimum). Investigate whether changes in signal represent alterations in protein abundance, localization, or modifications by complementing Western blot data with fluorescence microscopy or mass spectrometry.

What approaches can resolve contradictory results between GIS3 antibody and genetic expression data?

Contradictions between protein and mRNA levels are common and biologically significant. First, validate antibody specificity with positive and negative controls. Verify protein loading with total protein stains (Ponceau S or SYPRO Ruby) in addition to housekeeping protein controls. Consider post-transcriptional regulation mechanisms such as miRNA regulation, protein stability differences, or post-translational modifications affecting epitope recognition. Time-course experiments may reveal temporal discordance between transcription and translation. Polysome profiling can assess translational efficiency differences explaining the discrepancy.

How can I reliably quantify GIS3 protein levels across different subcellular fractions?

For subcellular fractionation studies, verify fraction purity using markers for different compartments (e.g., histone H3 for nuclear fraction, GAPDH for cytoplasmic fraction, Sec61 for ER). Normalize GIS3 signal to compartment-specific loading controls rather than whole-cell loading controls. Consider using fluorescence microscopy with the same antibody to visually confirm localization patterns. When calculating relative distribution, express results as percentage of total GIS3 signal across all fractions. Account for extraction efficiency differences between compartments by using spike-in controls.

Can GIS3 antibody be effectively utilized in super-resolution microscopy applications?

Adapting GIS3 antibody for super-resolution microscopy requires several optimization steps. Test both direct labeling (using commercially available antibody labeling kits) and secondary antibody approaches. For STORM/PALM applications, ensure high signal-to-noise ratio by increasing blocking stringency and optimizing antibody concentration. Fixation method significantly impacts epitope accessibility - compare paraformaldehyde, methanol, and glutaraldehyde fixation. Include specificity controls by imaging GIS3 knockout strains. Test different fluorophores to determine optimal photostability and brightness for your specific super-resolution platform.

What considerations are important when using GIS3 antibody for multiplexed protein detection?

For multiplexed detection, antibody compatibility with other primary antibodies must be established. Choose antibodies raised in different host species to allow species-specific secondary antibodies. When using antibodies from the same species, consider sequential detection with complete stripping between rounds or directly labeled primary antibodies. Test for cross-reactivity between antibodies by running single-antibody controls alongside multiplexed samples. For mass cytometry applications, metal-conjugated antibodies require validation of conjugation efficiency and signal-to-noise ratios compared to fluorescence-based detection.

How can GIS3 antibody be integrated into high-throughput screening approaches?

For high-throughput applications, optimize antibody concentration to minimize usage while maintaining sufficient signal. Automated liquid handling systems require validation of antibody performance in their specific buffer conditions and plastic ware. Consider developing a sandwich ELISA format for quantitative high-throughput screening, validating dynamic range, sensitivity, and reproducibility across plates. For cell-based screens, automated image analysis algorithms must be optimized for GIS3 signal detection and quantification with appropriate thresholds and segmentation parameters.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.